ORAMED PHARMACEUTICALS INC. Customer Breakdown
Customer relationships and concentrations across all retained periods. Named customers and their revenue are shown when disclosed. Anonymous customers, customer groups and sales channels are labelled separately. Receivable concentration measures unpaid balances, not revenue contribution. A biggest customer by revenue can be identified only from disclosed customer revenue. Missing names and amounts remain missing; identities are not assumed to match between periods.
| Period / as of | Customer / group | Category | Customer revenue | Share of revenue | Share of trade receivables | Basis and limitations |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |